Review Article

Herbal Active Ingredients: An Emerging Potential for the Prevention and Treatment of Papillary Thyroid Carcinoma

Yang Yang,1 Qin Chen,2 Wen-Ying Yu,1 Huan-Huan Zhang,1 Yu-Sen Zhong,1 Song-Zhao Zhang,2 Jia-Feng Wang,1 and Chen-Huan Yu1

1Key Laboratory of Experimental Animal and Safety Evaluation, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China
2Department of Clinical Laboratory Medicine, The Second Affiliated Hospital of Medicine School, Zhejiang University, Hangzhou 310009, China

Correspondence should be addressed to Chen-Huan Yu; yuchenhuan2002@163.com

Received 19 September 2019; Revised 28 November 2019; Accepted 5 December 2019; Published 31 January 2020

Academic Editor: Sami M. Nazzal

Copyright © 2020 Yang Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Papillary thyroid carcinoma (PTC) is the most common subtype of differentiated thyroid cancers in Asian coastal cities, where the patients have increased risk of potentially high or excessive iodine intake. Given the high metastasis and recurrence of patients with BRAFV600E mutation, the mortality rate of thyroid cancer has recently shown an upward trend. A variety of therapies, including surgery, radiotherapy, and chemotherapy, have been used to treat thyroid cancer, but these therapies still have limitations, including postoperative complications, drug resistance, poor efficacy, or serious side effects. Recent studies have shown the potential of active ingredients derived from herbal medicine in inhibiting PTC via various cell signaling pathways. Some plant-derived compounds, such as apigenin, genistein, and curcumin, are also known to prevent and treat PTC. This article summarizes the recent advances in the structure-functional impact of anti-PTC active ingredients and their effects on PTC cells and tumor microenvironments with an emphasis on their challenges from basic research to clinical practice.

1. Introduction

Thyroid cancer is the most common endocrine neoplasms accounting for 5.0% of head and neck cancers [1]. Studies have shown that approximately 95% of thyroid cancers originate from thyroid follicular epithelial cells, including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and anaplastic thyroid cancer (ATC); in addition, a small amount is medullary thyroid carcinoma (MTC) originated from parafollicular cells in the thyroid gland [2, 3]. Among those subtypes, approximately 70% to 80% of all types of thyroid cancers is PTC. Epidemiological studies have revealed that PTC prevalence has increased at an average annual rate of nearly 4% in recent years, and most patients with thyroid cancer suffer from PTC, which is also the main driver of the increased incidence of thyroid cancer [4–7]. PTC has become one of the seven major causes of new malignant tumors among women, and almost all thyroid cancers among children are classified as PTC [8, 9]. Among patients with PTC, the accompanying cervical lymph node metastasis rate reaches 5.4% to 13% after surgery [10–12]. The most common clinical therapies being used for managing PTC include surgery, chemotherapy, and physiotherapy, all of which are hindered by recurrence and metastasis.

With irregular living habits (such as sleep deprivation and long-term high calorie diet intaking) and environmental factors (such as electromagnetic radiation), endocrine disorders including thyroid dysfunction become more and more common to human beings [13, 14]. Both genetic and environmental factors act on thyroid cells and ultimately lead to the transformation of normal thyroid cells into tumor cells. During PTC pathogenesis, some critical genes (including BRAF, RET, KRAS, and PI3KCA) through mutation or chromosomal translocation continuously activate their dependent downstream signaling pathways, such as
mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/AKT, nuclear factor-κB (NF-κB), and Notch-1, and thereby lead to cellular proliferation, migration, invasion, and angiogenesis [15–17]. Recently, emerging clinical trials and experimental researches also demonstrated that some noncoding RNA expressions, such as miRs-21, -34b, -221/222, lncRNA ATB, lncRNA H19, lncRNA HOXA-AS2, circITCH, and circZFR, showed significant association with aggressive clinicopathologic feature in PTC, including tumor size, lymphovascular invasion, lymph node metastases, and presence of BRAFV600E mutation [17–21]. Despite the advances in tumorigenesis, metastasis, and therapy, the underlying mechanism of PTC remains unclear. Therefore, further studies on the pathogenesis, prevention, and treatment of PTC in the pharmaceutical circle should be conducted.

Traditional herbal medicine has an important position in PTC prevention and treatment in Asian countries for a long history. Many active ingredients derived from food and herbs could prevent the development of PTC. Characterized by their mildness and long-lasting action, limited side effects, long-term use, and multitarget regulation, these herbal active ingredients provide many advantages and cannot be replaced by western medicine [22–24]. They not only inhibit the proliferation and promote the apoptosis of PTC cells by regulating critical signal pathways but also improve the immunity of patients and decrease stress response [25–27] as shown in Table 1. This study discusses the role of phytochemicals in thyroid signaling modulation and their possible beneficial or unfavorable effects on the risk of thyroid cancer.

2. Tannins (Phenolic Acids)

On the basis of their chemical structure, tannins can be categorized into hydrolyzable, condensed, and complex tannins. Condensed tannins manifest numerous pharmacological effects, such as antioxidant, antitumor, antihuman immunodeficiency virus, anti-inflammatory, and antimicrobial properties, and are widely found in many medicinal plants and dietary sources, including fruits, nuts, grains, spices, and beverages [58, 59]. Similarly, hydrolyzable tannins have a variety of pharmacological effects, such as antiviral, antibacterial, antitumor, hypolipidemic, and antioxidant properties, and serve as pharmacodynamic bases of many commonly used medicinal plants [60–64].

Epigallocatechin-3-gallate (EGCG), which is the major catechin in tea, shows remarkable protective effects against several chronic inflammatory and cardiovascular diseases, such as cancer, obesity, diabetes, myocardial ischemia, bronchitis, and asthma [65–70]. EGCG exerts chemopreventive effects on various tumors and selectively inhibits various cancer cell proliferation, metastasis, and invasion via regulating VEGF, MAPK, PI3K, and Wnt pathways [71–73]. Wu et al. treated human PTC cell lines (TT and TPC-1) and the ATC cell line (ARO) with EGCG at concentrations of 10–200 μM and observed that EGCG concentration-dependently inhibited the proliferation of these PTC cells and made the cell cycle arrest at the S phase. EGCG also induces the apoptosis of both PTC and ATC cells by inhibiting the EGFR-dependent ERK pathway. In addition, it could inhibit growth and angiogenesis but induce the apoptosis of PTC xenograft tumors in nude mice [28]. De Amicis et al. demonstrated that treatment with EGCG at the doses of 10–60 mM inhibited the proliferation of PTC (FB-2) and FTC (WRO) cell lines through suppressing the phosphorylation of AKT and ERK1/2; furthermore, EGCG reduced cell motility and migration by modulating cell adhesion, reorganizing the actin cytoskeleton, increasing E-cadherin expression, and suppressing SNAIL, ZEB, TWIST, Vimentin, N-cadherin, and α5-integrin, thereby indicating that EGCG inhibited the proliferation and epithelial- to-mesenchymal transition (EMT) of PTC cells [29].

Resveratrol is a polyphenolic phytoalexin with antioxidant and chemopreventive activities [74]. This material has a wide spectrum of targets, including COX2, Sirt1, p53, and miR-17/miR-20b [75], and can inhibit multiple cellular signaling pathways, which were associated with carcinogenesis and progression [76]. Plenty of studies over the past decades have shown that resveratrol downregulated thyroid cancer stem cell markers (including aldehyde dehydrogenases (ALDH), SOX2, OCT4, and NANOG), decreased proliferation and invasiveness, induced apoptosis, reduced ALDH-associated cancer cell stemness, and upregulated thyroid differentiation markers TTF-1 and NIS, which contributed to radioiodine uptake in the treatment of aggressive thyroid cancers [30]. Notably, it was more effective on the redifferentiation of PTC than that of ATC with a high CSC content [22, 30].

Punicalagin is a large polyphenol compound extracted from pomegranates and is classified as an ellagitannin, a family of hydrolyzable tannins [77]. Punicalagin not only induces the cell death of the PTC cell line BCPAP by triggering ATM-mediated DNA damage response [31] but also leads to the G0/G1 phase arrest and senescence-associated secretory phenotype by triggering NF-κB activation [32].

Curcumin is a natural polyphenol extracted from Rizoma curcumaee longae, which is the main component of Curcuma longa. Curcumin is one of the best-selling natural edible pigments all over the world and is widely used as a food additive approved by the World Health Organization and most countries. It has various chemopreventive properties, such as antioxidant, antitumoral, antiviral, anti-inflammatory, antihepatotoxic, antidiabetic, hypolipidemic, and neuroprotective properties [78–82]. Several studies have also revealed that curcumin induced PTC cell BCPAP apoptosis and cell arrested at the G2/M phase with the concentration increased involving in multitargeting mechanisms, including the activation of reactive oxygen species (ROS)-independent DNA damage by recruiting ATM-mediated DNA damage response [31], the activation of endoplasmic reticulum (ER) stress by disrupting intracellular calcium homeostasis [34], the inhibition of the β-catenin pathway [35], and the modulation of the mitochondrial Bcl-2/Bax pathway [36]. Furthermore, curcumin inhibits invasion and metastasis in PTC cells by upregulating E-cadherin expression and downregulating matrix
Curcumin can also inhibit TGF-β1-induced EMT via the downregulating phosphorylation of Smad2/3, which in turn inhibits the metastasis of human PTC BCPAP cells [38]. Hypoxia plays a crucial role in tumor metastasis, which is the leading cause of death in patients with PTC [83]. Curcumin significantly reduces the production of hypoxia-induced ROS and the binding capacity of HIF-1α to its downstream oncogenes.

| Phytochemicals | Cell lines/patient | Dose (µM) | Mechanisms | References |
|----------------|--------------------|-----------|-------------|------------|
| EGCG           | TPC-1, ARO, FB-2, WRO | 10–200, 10–60 | Induce apoptosis via inhibiting EGFR/RAS/ERK pathway | [28, 29] |
| Resveratrol     | TPC-1, BCPAP       | 5–50       | Induce apoptosis and differentiation of CSC | [22, 30] |
| Punicalagin     | BCPAP              | 12.5–100   | Induce cell death by triggering ATM-mediated DNA damage; inhibit senescent growth via NF-κB pathway. | [31, 32] |
| Curcumin        | TPC-1, BCPAP, K1   | 12.5–50    | Induce apoptosis via (1) induction of ROS-independent DNA damage by triggering an ATM-activated Chk2-Cdc25C-Cdc2 pathway; (2) activation of ER stress by disruption of intracellular calcium homeostasis; (3) inhibition of β-catenin pathway; (4) modulation of mitochondrial Bcl-2/Bax pathway. Inhibit invasion and metastasis via (1) upregulating E-cadherin and downregulating MMP-9; (2) reversing EMT by inhibiting TGF-β1/Smad2/3 pathway. | [33, 34, 35, 36, 37, 38] |
| Apigenin        | BCPAP, PCC13 with BRAFV600E, primary TPC cells | 12.5–100 | Arrest the cell growth in G2/M phase; induce autophagy via ROS-mediated DNA damage. Synergistic effects with akt inhibitor | [39, 40] |
| Quercetin       | BCPAP              | 50–75      | Induce apoptosis via inhibiting Hsp90 and caspase-3/parp pathways | [41, 42] |
| Myricetin       | SNU-790            | 25–50      | Induce apoptosis via inhibiting the caspase-dependent mitochondrial pathway | [43] |
| Icariin         | SW579, TPC1        | 20–50      | Induce apoptosis via downregulation of miR-625-3p and inactivation of PI3K/Akt and MEK/ERK signaling pathways | [44] |
| Flavokawain B   | ARO, WRO, TPC-1    | 3.5–25     | Induce autophagy via regulating AMPK/mTOR pathway | [45] |
| Genistein       | BHP10-3, BCPAP, IHH4 | 9.5–300    | Inhibit β-catenin and EMT | [46] |
| Silibinin       | TPC-1              | 10–100     | Suppress migration and MMP-9 expression via ERK pathway | [47] |
| Ginsenoside Rg1 | IHH-4, BCPAP       | 5–40       | Inhibit cell malignancies by upregulating Cx31 | [48] |
| Ginsenoside Rg3 | TPC-1, BCPAP       | 6.25–100   | Inhibit invasion and metastasis via reducing rho GTPase | [49] |
| Capsaicin       | BCPAP              | 25–100     | Inhibit apoptosis via activation of TRPV1 and subsequently regulating EMT | [50] |
| Berberine       | TPC-1              | 10–160     | Induce apoptosis, G0/G1 cell cycle arrest and migration via PI3K/Akt and MAPK pathways | [51] |
| Paclitaxel      | PTC patient with SCC component | Weekly 80 mg/m² | The response rate was 67% and the clinical benefit rate was 100% | [52] |
| Pseudolaric acid B | SW1579            | 1.25–5     | Induce G2/M cell cycle arrest by activating autophagy by decreasing nuclear p53 expression | [53] |
| Shikonin        | 8505c, 8305c, FTC133, BCPAP, C643, TPC-1, IHH4, K1, HTori-3 | 3–6       | Induce apoptosis via suppression of ERK/Akt and DNMT1, and activation of p16/Rb and caspase-3-dependent mitochondrial pathways; Inhibit migration and invasion by suppressing EMT and expression of slug and MMP-2, -9, and -14. | [54–56, 54] |
| Allicin          | HTh-7              | 10         | Activating autophagy via inactivation of akt and S6 pathways | [57] |

EGCG: Epigallocatechin-3-gallate; ATM: ataxia telangiectasia-mutated; ROS: reactive oxygen species; EMT: epithelial-to-mesenchymal transition; CSC: cancer stem cell; ER: endoplasmic reticulum; PTC: papillary thyroid carcinoma; SCC: squamous cell carcinoma; EGFR: epidermal growth factor receptor.
and weakens the migration of PTC cells under hypoxic conditions [84]. Meanwhile, when combined with sorafenib, curcumin significantly inhibits the apoptosis of FTC133 cells via PI3K/AKT and ERK pathways; moreover, compared with chemotherapy drugs, curcumin has lower cytotoxic effects on normal cells [85]. When cotreated with other natural extracts such as spirulina and Boswellia, curcumin can effectively reduce the size of benign thyroid nodules and restore thyroid hormonal dysfunction, thereby preventing the progress of PTC canceration [86].

3. Flavonoids

Flavonoids are a group of phenolic antioxidants with strong biological activity that have been widely used in pharmaceutical and food additives. Some flavonoids, such as soy genistein, naringenin, phloretin, and chrysin, are structurally similar to estrogen and have little or weak estrogen-like activity. Moreover, different flavonoids perform selective functions during the estrogen receptor subtype stimulation [87, 93].

Apigenin and quercetin are flavonoids that are most commonly found in a variety of fruits, vegetables, and herbs [94, 95]. Treatment with apigenin at concentrations of 12.5–100 μM can inhibit the proliferation of BCPAP cells arrested in the G2/M phase and induce autophagy via ROS-mediated DNA damage [39]. Moreover, combining with apigenin and AKT inhibitors enhances the antitumor effects of radioiodine in both BRAFV600E-expressed rat thyroid cells and primary cultured PTC cells from TRPV/PV mice [40]. Unlike those of apigenin, the effects of quercetin on thyroid cells have been disputed. Some studies showed that 1.25–20 μM of quercetin inhibited normal thyroid cell growth in association with the inhibition of the insulin-induced PI3K/AKT pathway. Moreover, quercetin decreases the expression of thyroid-stimulating hormone-mediated thyroid-restricted gene sodium/iodide symporter (NIS) [96, 97]. By contrast, treatment with 50–75 μM quercetin shows an excellent anticancer activity by inducing S phase arrest and apoptosis via Hsp90 and Caspase-3/PARP pathways in BCPAP cells [41, 42]. Similarly, myricetin, of which the B ring presents one more hydroxyl group at the 5′ position compared with quercetin, dependently induces apoptosis and DNA condensation of SNU-790 PTC cells, which also involves caspase-dependent mitochondrial dysfunctions [43].

Icariin is the main active ingredient of Epimedium davidii Franch. and has gained much attention because of its erektenogenic and neurotrophic effects [98]. Recently, many studies have demonstrated the application of icariin on hormone-dependent neoplasia and in the treatment of prostatic, ovarian, and thyroid cancers [44, 99–101]. Icariin can inhibit cell proliferation, migration, and invasion via downregulating miR-625-3p and suppressing PI3K/AKT and ERK pathways in both SW579 and TPC1 cells [39].

Flavokawain B is a hepatotoxic constituent extracted from kava root [102] and shows potent cytotoxicity by inducing ROS-mediated apoptotic and autophagic cell death in various tumor cells [103, 104]. This material also inhibits cell viability, migration, and invasion and causes autophagy via the activation of the AMPK/mTOR pathway in thyroid cancer ARO, WRO, and TPC-1 cells [45].

Genistein is the main active ingredient of Leguminosae. This isoflavone inhibits the invasion and metastasis of the PTC-derived BHP10-3 cell (with RET/PTC 1 rearrangement), BCPAP, and IHH4 (with BRAFV600E mutation) by inhibiting β-catenin and EMT [46]. However, genistein upregulates most thyroid transcript signals, except for thyroid peroxidase, in zebrafish embryos, thereby indicating potential disruptions [105].

Silibinin is a natural hepatoprotective drug and has excellent antioxidant and anticancer properties. It also induces apoptosis, autophagy, makes cell cycle arrest, and inhibits oncogenic miRNAs which is involved in the PTC tumorigenesis [106]. Previous studies showed that it suppressed cell migration and MMP-9 expression by regulating the ERK pathway in thyroid cancer cells [47].

4. Saponins

Saponins are steroid or triterpenoid glycosides commonly found in plants. Extensive studies have shown that saponins have various pharmacological effects, including hypoglycemic, antitumor, anti-inflammatory, immunomodulatory, and vasoprotective properties, and thus they have been widely used for preventing and treating cardiovascular and immunodeficiency diseases [107]. Ginsenosides are by far the most investigated group of saponins with a triterpenoid dammarane skeleton and are the main active ingredients of the ginseng genus (Panax ginseng C. A. Mey. Panax notoginseng (Burk.) F. H. Chen and Panax quinquefolium L.) in Araliaceae and Gynostemma pentaphyllum (Thunb) Makino. in Cucurbitaceae [108, 109]. At high concentrations (>100 μM), ginsenosides exert cytotoxic and haemolytic effects, while treatment at low concentrations (10–100 μM) inhibits the proliferation of PTC cells, thereby indicating its multidirectional effects on cancer cells [110]. Despite similarities in the structure of dexamethasone, both 20(S)-protopanaxadiol (PPD)-type ginsenosides (such as Rb1, Rb2, Rc, Rd, Rh2, and Compound K) and
20(S)-protopanaxatriol (PPT)-type ginsenosides (such as Re, Rf, Rg1, and Rh1) do not have any effects on glucocorticoid receptor transactivation or transrepression [111]. However, they exert synergistic anti-inflammatory effects when in combination with glucocorticoids at the low doses [112]. Previous studies show that PPT-type ginsenosides (Rg1 and Rg3) can reduce the proliferation, migration, and invasion of PTC cells by upregulating Cx31 and inhibiting Rho GTPase to an alternate cytoskeleton [48, 49]. Furthermore, Rg3 remarkably reduces the expression of the VEGF-C protein in TPC-1, BCPAP, C643, and Ocut-2c cells and inhibits lymph node metastasis in mice [49]. Structure-activity relationships elucidate the association between chemical structures and the anticancer activities of a series of ginsenosides. As shown in Table 2, the anticancer activities of ginsenosides generally take the descending order of CKactivities of ginsenosides as series of ginsenosides. As shown in Table 2, the anticancer activities of ginsenosides generally take the descending order of CK > Rg1 ≈ 20(S)-Rh2 ≈ 20(S)-Rg3 > PPT > PPD, thereby suggesting that the ginsenoside with less polar chemical structures has stronger cytotoxic effects on PTC cells [50, 51].

5. Other Bioactivities

Capsaicin (CAP), a major active component of chili peppers, selectively binds to transient receptor potential vanilloid type 1 (TRPV1). CAP (25–100 μM) dose-dependently suppresses the migration, invasion, and adhesion of BCPAP cells by activating TRPV1 and subsequently regulating EMT [52].

Berberine is an isooquinoline alkaloid mainly isolated from Coptis chinensis Franch. and Berberis wilsonae Hemsl. et Wils. Numerous studies have shown that it had multiple pharmacological effects, including antimicrobial, hypoglycemic, anti-inflammatory, antibacterial, and antineoplastic properties. Berberine can also induce mitochondrial apoptosis, trigger G0/G1 cell cycle arrest, and suppress the migration of TPC-1 cells via inhibiting PI3K/AKT and MAPK pathways [113].

Paclitaxel is a tetracyclic diterpenoid derived from the dried roots, branches, leaves, and barks of Taxus chinensis. Paclitaxel is a first-line chemotherapeutic agent for PTC patients with a squamous cell carcinoma component, of which response rates are 67% and the clinical benefit rate (PR + SD) is 100%. Therefore, weekly paclitaxel may be applied as effective adjuvant chemotherapy after surgery [114].

Pseudolaric acid B (PAB) is a diterpenoid acid extracted from the root barks or barks near the roots of Pseudolarix amabilis (Nelson) Rehd. (Pinaceae) and is known as an antitubulin therapeutic agent that can suppress microtubule assembly to inhibit the proliferation of cancer cells [53, 115]. PAB can also inhibit the proliferation, invasion, and migration of SW579 cells by preventing the regulation of Bcl-2 and Beclin-1 expression but decreases the expression of nuclear p53 and induces G2/M cell cycle arrest by increasing the ratio of autophagic cells [54].

Shikonin is a natural bioactive naphthoquinone derived from Lithospermum erythrorhizon Sieb. et Zucc (also called Zi Cao in Asia). It has been recently considered as a natural food additive and antitumor agent for breast cancer, leukemia, hepatoma, and nonsmall cell lung cancer [55, 56, 116]. Previous studies reveal that shikonin dramatically inhibits the migration and invasion of PTC cells via suppressing EMT and inhibiting the expressions of slug and MMP-2, -9, and -14. Furthermore, shikonin induces PTC cell apoptosis by targeting several signaling pathways, suppressing ERK/AKT and DNMT1, and activating p16/Rb and caspase-3-dependent mitochondrial pathways [57, 117, 118]. The oral administration of 2.0 mg/kg shikonin does not cause any liver injury in mice, thereby indicating its safety [117].

Allicin, as another well-known natural food additive, is mainly isolated from garlic. Allicin inhibits the proliferation of cancer cells, induces cell apoptosis, and increases the intracellular levels of ROS [57, 118]. It can also improve multidrug resistance in thyroid cancer cells via inducing autophagy but inactivating AKT and S6 pathways [119].

6. Conclusions and Outlook

Although the problems of overdiagnosis and overtreatment now seem to be acknowledged, how to acquire survival benefit for PTC patients becomes to be a basic challenge [120]. Therefore, it is obviously important to explore new mild strategies to prevent and treat PTC. Phytochemicals have received much attention over the past three decades as potential sources of new candidates for cancer chemoprevention and treatment. Given the fact that many available anticancer drugs are derived from plant substances (e.g., taxol, vinblastine, homoharringtonine, β-elemene, indole-3-carbinol) as prototypes, this review focuses on herbal active ingredients with high potentials for the prevention and treatment of PTC. The benefits of these ingredients in PTC prevention and treatment have been well investigated, but their underlying mechanism and direct molecular targets remain unclear. Due to the latent toxicological, low bioavailability, foreseeable multidrug resistance, and deficient clinical trials, the extensive assessment of those untapped natural compounds on humanized immune system mouse models and achievable doses and drug delivery systems compatible for human studies still need to be further explored. Moreover, the development and progression of tumors are strongly associated with the physiological and pathological characteristics of the tumor microenvironment (TME) [121], in which hypoxia, chronic inflammation, oxidative stress, and acidosis contribute to cancer progression, including immune escape, angiogenesis, and metastasis. Given their multihydroxy structures, most phytochemicals with antioxidant and anti-inflammatory potentials can be ponderant on the improvement of TME profiles. According to the different features of cell subsets in TME, the patients could derive benefits from the intervention of multidrug combination. However, the effectiveness of herbal active ingredients on TME has been rarely reported. The application of those strategies might promote the clinical translation of these herbal active ingredients for PTC prevention and treatment.
Table 2: The structure-activity relationship of ginsenosides.

| Basic structure | Compounds | R1 | R2 | R3 | IC50 (μM) |
|-----------------|-----------|----|----|----|-----------|
| Protopanaxadiol type (PPD) | Rb1 | -Glc2-Glc | -H | -Glcα-Glc | >200 |
| | Rb2 | -Glc2-Glc | -H | -Glcα-Ara (p) | >200 |
| | Rc | -Glc2-Glc | -H | -Glcα-Ara (f) | >200 |
| | Rd | -Glc2-Glc | -H | -Glc | >200 |
| | Rg1 | -Glc2-Glc | -H | -H: 20 (S) | 50 |
| | Rh2 | -Glc | -H | -H: 20 (S) | 45 |
| | CK | -Glc | -H | -Glcα-Ara (p) | 10 |
| | PPD | -H | -H | -H | 80 |
| Protopanaxatriol type (PPT) | Re | -Glc2-Rha | -OH | -Glc | >200 |
| | Rf | -Glc2-Glc | -OH | -H | >200 |
| | Rg1 | -Glc | -OH | -Glc | 40 |
| | Rg2 (S) | -Glc2-Rha | -OH | -H: 20 (S) | >200 |
| | Rh1 | -Glc | -OH | -H | >200 |
| | Rg2 (R) | -Glc2-Rha | -OH | -H: 20 (R) | >200 |
| | PPT | -H | -OH | -H | 70 |

a: inhibition of thyroid cancer cells (for 48 h).

Conflicts of Interest

The authors declare no conflicts of interests.

Acknowledgments

This work is supported by Zhejiang Natural Science Foundation (No. LQ16H200003) and Zhejiang Disciplinary Construction of Laboratory Animal Genetic Engineering (No. 201604).

References

[1] J. J. Wiltshire, T. M. Drake, L. Uttley, and S. P. Balasubramanian, "Systematic review of trends in the incidence rates of thyroid cancer," *Thyroid*, vol. 26, no. 11, pp. 1541–1552, 2016.
[2] C. D. Seib and J. A. Sosa, "Evolving understanding of the epidemiology of thyroid cancer," *Endocrinology and Metabolism Clinics of North America*, vol. 48, no. 1, pp. 23–35, 2019.
[3] D. Rusinek, E. Chmielik, J. Krajewska et al., "Current advances in thyroid cancer management: are we ready for the epidemic rise of diagnoses?" *International Journal of Molecular Sciences*, vol. 18, no. 8, p. 1817, 2017.
[4] C. C. Lubitz and J. A. Sosa, "The changing landscape of papillary thyroid cancer: epidemiology, management, and the implications for patients," *Cancer*, vol. 122, no. 24, pp. 3754–3759, 2016.
[5] M. Hajeer, H. Awad, N. Abdullah, G. Almuhaisen, and L. Abudala, "The rising trend in papillary thyroid carcinoma: true increase or over diagnosis?" *Saudi Medical Journal*, vol. 39, no. 2, pp. 147–153, 2018.
[6] Y. Ito, A. Miyauchi, H. Oda et al., "Appropriateness of the revised Japanese guidelines’ risk classification for the prognosis of papillary thyroid carcinoma: a retrospective analysis of 5,845 papillary thyroid carcinoma patients," *Endocrine Journal*, vol. 66, no. 2, pp. 127–134, 2019.
[7] H. J. Kim, H. K. Park, D. W. Byun et al., "Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area," *European Journal of Nutrition*, vol. 57, no. 2, pp. 809–815, 2018.
[8] M. Fridman, A. K.-Y. Lam, O. Krasko, K. W. Schmid, D. I. Brananov, and Y. Demidchik, "Morphological and clinical presentation of papillary thyroid carcinoma in children and adolescents of belarus: the influence of radiation exposure and the source of irradiation," *Experimental and Molecular Pathology*, vol. 98, no. 3, pp. 527–531, 2015.
[9] P. Wang, L. Lv, F. Qi, and F. Qiu, "Increased risk of papillary thyroid cancer related to hormonal factors in women," *Tumor Biology*, vol. 36, no. 7, pp. 5127–5132, 2015.
[10] X.-Y. Zhang, H.-I. Song, Z.-L. Qiu et al., "Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131I," *Endocrine*, vol. 62, no. 1, pp. 149–158, 2018.
[11] B. Yan, Y. Hou, D. Chen, J. He, and Y. Jiang, "Risk factors for contralateral central lymph node metastasis in unilateral cN0 papillary thyroid carcinoma: a meta-analysis," *International Journal of Surgery*, vol. 59, pp. 90–98, 2018.
[12] J. Mansour, D. Sagiv, E. Alon, and Y. Talmi, "Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma," *The Journal of Laryngology & Otology*, vol. 132, no. 1, pp. 8–13, 2018.
[13] H. Sadeghi, M. Rafei, M. Bahrami, A. Haghighost, and Y. Shahani, "Attributable risk fraction of four lifestyle risk factors of thyroid cancer: a meta-analysis," *Journal of Public Health*, vol. 40, no. 2, pp. e91–e98, 2018.
[14] C. M. Kitahara, D. L. Preston, G. Neta et al., "Occupational radiation exposure and thyroid cancer incidence in a cohort of U.S. radiologic technologists, 1983–2013," *International Journal of Cancer*, vol. 143, no. 9, pp. 2145–2149, 2018.
[15] X. L. Li, X. D. Mao, G. F. Chen et al., "High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules," *Medicine (Baltimore)*, vol. 98, no. 28, Article ID e16343, 2019.
[16] J. Ming, Z. Liu, W. Zeng et al., "Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer," *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 8, pp. 15155–15162, 2015.
[17] M. I. Abdullah, S. M. Junit, K. L. Ng, J. J. Jayapalan, B. Karikalan, and O. H. Hashim, “Papillary thyroid cancer: genetic alterations and molecular biomarker investigations,” International Journal of Medical Sciences, vol. 16, no. 3, pp. 450–460, 2019.

[18] A. Zembksa, A. Jawiarczyk-przybyłowska, B. Wojtczak, and M. Bolanowski, "MicroRNA expression in the progression and aggressiveness of papillary thyroid carcinoma," Anti-cancer Research, vol. 39, no. 1, pp. 33–40, 2019.

[19] M.-R. Mahmoudian-Sani, A. Jalali, M. Jamshidi et al., "Long non-coding RNAs in thyroid cancer: implications for pathogenesis, diagnosis, and therapy," Oncology Research and Treatment, vol. 42, no. 3, pp. 136–142, 2019.

[20] M. Wang, B. Chen, Z. Ru, and L. Cong, "CircRNA circ-ITCH suppresses papillary thyroid cancer progression through miR-22-3p/CBL/β-catenin pathway," Biochemical and Biophysical Research Communications, vol. 504, no. 1, pp. 283–288, 2018.

[21] N. Peng, L. Shi, Q. Zhang, Y. Hu, N. Wang, and H. Ye, "Microarray profiling of circular RNAs in human papillary thyroid carcinoma," PLoS One, vol. 12, no. 3, Article ID e0170287, 2017.

[22] H. J. Kang, Y.-K. Youn, M.-K. Hong, and L. S. Kim, "Antiproliferation and redifferentiation in thyroid cancer cell lines by polyphenol phytochemicals," Journal of Korean Medical Science, vol. 26, no. 7, pp. 893–899, 2011.

[23] A. B. Oyenhi and C. Smith, "Are polyphenol antioxidants at the root of medicinal plant anti-cancer success?" Journal of Ethnopharmacology, vol. 229, pp. 54–72, 2019.

[24] Q. Xiao, Y. Park, A. R. Hollenbeck, and C. M. Kitaraha, "Dietary flavonoid intake and thyroid cancer risk in the NIH-AARP diet and health study," Cancer Epidemiology Biomarkers & Prevention, vol. 23, no. 6, pp. 1102–1108, 2014.

[25] H.-J. Shin, K.-A. Hwang, and K.-C. Choi, "Antitumor effect of various phytochemicals on diverse types of thyroid cancers," Nutrients, vol. 11, no. 1, p. 125, 2019.

[26] F. Pistollato, M. Masias, P. Agudo, F. Giampieri, and D. Wu, Z. Liu, J. Li et al., "Icariin inhibits cell proliferation and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines," Journal of Cellular Physiology, vol. 228, no. 10, pp. 2054–2062, 2013.

[27] H. Hardin, X.-M. Yu, A. D. Harrison et al., "Generation of novel thyroid cancer stem-like cell clones," The American Journal of Pathology, vol. 186, no. 6, pp. 1662–1673, 2016.

[28] X. Yao, X. Cheng, L. Zhang et al., "punicalagin from pomegranate promotes human papillary thyroid carcinoma BCPAP cell death by triggering ATM-mediated DNA damage response," Nutrition Research, vol. 47, pp. 63–71, 2017.
metastasis," Journal of Cancer, vol. 10, no. 3, pp. 737–748, 2019.
[47] S.-J. Oh, S. P. Jung, J. Han et al., “Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells,” Oncology Reports, vol. 29, no. 4, pp. 1343–1348, 2013.
[48] L. Xu, S.-W. Chen, X.-Y. Qi, X.-X. Li, and Y.-B. Sun, “Ginsenoside improves papillary thyroid cancer cell malignancies partially through upregulating connexin31,” The Kaohsing Journal of Medical Sciences, vol. 34, no. 6, pp. 313–320, 2018.
[49] W. Wu, Q. Zhou, W. Zhao et al., “Ginsenoside Rg3 inhibition of thyroid cancer metastasis is associated with alternation of actin skeleton,” Journal of Medicinal Food, vol. 21, no. 9, pp. 849–857, 2018.
[50] K. Quan, Q. Liu, J. Y. Wan et al., “Rapid preparation of rare ginsenosides by acid transformation and their structure-activity relationships against cancer cells,” Scientific Reports, vol. 5, no. 1, p. 8598, 2015.
[51] H. Dong, L.-P. Bai, V. K. W. Wong et al., “The in vitro structure-related anti-cancer activity of ginsenosides and their derivatives,” Molecules, vol. 16, no. 12, pp. 10619–10630, 2011.
[52] S. Xu, L. Zhang, X. Cheng, H. Yu, J. Bao, and R. Lu, “Capsaicin inhibits the metastasis of human papillary thyroid carcinoma BCPAP cells through the modulation of the TRPV1 channel,” Food & Function, vol. 9, no. 1, pp. 344–354, 2018.
[53] G.-d. Yao, J. Yang, X.-x. Li et al., “Blocking the utilization of glucose induces the switch from senescence to apoptosis in pseudolaric acid B-treated human lung cancer cells in vitro,” Acta Pharmacologica Sinica, vol. 38, no. 10, pp. 1401–1411, 2017.
[54] J. Yu, P. Ren, T. Zhong et al., “Pseudolaric acid B inhibits proliferation in SW579 human thyroid squamous cell carcinoma,” Molecular Medicine Reports, vol. 12, no. 5, pp. 7195–7202, 2015.
[55] F. Wang, X. Yao, Y. Zhang, and J. Tang, “Synthesis, biological function and evaluation of Shikonin in cancer therapy,” Fitoterapia, vol. 134, pp. 329–339, 2019.
[56] Q. Yang, M. Ji, H. Guan, B. Shi, and P. Hou, “Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 12, pp. E1909–E1917, 2013.
[57] J. Borlinghaus, F. Albrecht, M. Gruhlke, I. Nwachukwu, and A. Slusarenko, “Allicin: chemistry and biological properties,” Molecules, vol. 19, no. 8, pp. 12591–12618, 2014.
[58] A. P. Laddha and Y. A. Kulkarni, “Tannins and vascular complications of diabetes: an update,” Phytotherapy, vol. 56, pp. 229–245, 2019.
[59] Y. Cai, J. Zhang, N. G. Chen et al., “Tannins and vascular complications of diabetes: an update,” Phytotherapy, vol. 56, pp. 229–245, 2019.
[60] C. Liu, D. Cai, L. Zhang et al., “Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA,” Antiviral Research, vol. 134, pp. 97–107, 2016.
[61] Z.-H. Jiang, X.-Y. Wen, T. Tanaka et al., “Cytotoxic hydrolyzable tannins from Balanophora japonica,” Journal of Natural Products, vol. 71, no. 4, pp. 719–723, 2008.
[62] J.-B. Liu, Y.-S. Ding, Y. Zhang et al., “Anti-inflammatory hydrolyzable tannins from myricaria bracteata,” Journal of Natural Products, vol. 78, no. 5, pp. 1015–1025, 2015.
[63] M. Costa, S. P. Alves, A. Cappucci et al., “Effects of condensed and hydrolyzable tannins on rumen metabolism with emphasis on the biohydrogenation of unsaturated fatty acids,” Journal of Agricultural and Food Chemistry, vol. 66, no. 13, pp. 3367–3377, 2018.
[64] D. Y. Lee, H. W. Kim, H. Yang, and S. H. Sung, “Hydrolyzable tannins from the fruits of Terminalia chebula Retz and their α-glucosidase inhibitory activities,” Phytochemistry, vol. 137, pp. 109–116, 2017.
[65] L. Xing, H. Zhang, R. Qi, R. Tsao, and Y. Mine, “Recent advances in the understanding of the health benefits and molecular mechanisms associated with green tea polyphenols,” Journal of Agricultural and Food Chemistry, vol. 67, no. 4, pp. 1029–1043, 2019.
[66] Q. Y. Peng, P. V. Thanikachalam, and S. Ramamurthy, “Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases,” Journal of Ethnopharmacology, vol. 210, pp. 296–310, 2018.
[67] D.-L. Hu, G. Wang, J. Yu et al., “Epigallocatechin-3-gallate modulates long non-coding RNA and mRNA expression profiles in lung cancer cells,” Molecular Medicine Reports, vol. 19, no. 3, pp. 1509–1520, 2019.
[68] S. K. Dhatwalia, M. Kumar, P. Bhardwaj, and D. K. Dhawan, “White tea-a cost effective alternative to EGCG in fight against benzo (a) pyrene (BaP) induced lung toxicity in SD rats,” Food and Chemical Toxicology, vol. 131, Article ID 110551, 2019.
[69] N. Yang and Y.-X. Shang, “Epigallocatechin gallate ameliorates airway inflammation by regulating Treg/Th17 imbalance in an asthmatic mouse model,” International Immunopharmacology, vol. 72, pp. 422–428, 2019.
[70] E. Casanova, J. Salvadó, A. Crescenti, and A. Gibert-Ramos, “Epigallocatechin gallate modulates muscle homeostasis in type 2 diabetes and obesity by targeting energetic and redox pathways: a narrative review,” International Journal of Molecular Sciences, vol. 20, no. 3, p. 532, 2019.
[71] M. Pervin, K. Unno, T. Ohishi, H. Tanabe, N. Miyoshi, and Y. Nakamura, “Beneficial effects of green tea catechins on neurodegenerative diseases,” Molecules, vol. 23, no. 6, p. 1297, 2018.
[72] V. Bhardwaj and A. Mandal, “Next-generation sequencing reveals the role of epigallocatechin-3-gallate in regulating putative novel and known microRNAs which target the MAPK pathway in non-small-cell lung cancer A549 cells,” Molecules, vol. 24, no. 2, p. 368, 2019.
[73] A. Negri, V. Naponelli, F. Rizzi, and S. Bettuzzi, “Molecular targets of epigallocatechin-gallate (EGCG): a special focus on signal transduction and cancer,” Nutrients, vol. 10, no. 12, p. 1936, 2018.
[74] H. Li, N. Xia, S. Hasselwander, and A. Daiber, “Resveratrol and vascular function,” International Journal of Molecular Sciences, vol. 20, no. 9, p. 2155, 2019.
[75] Y. Song, Y. Chen, Y. Li et al., “Resveratrol suppresses epithelial-mesenchymal transition in GBM by regulating smad3,” The Journal of Clinical and Experimental Neurology, vol. 12, no. 5, p. 925, 2019.
[76] F. Giamogante, I. Marrocchi, L. Cervoni, M. Eufemi, S. Chichiarelli, and F. Altieri, “Punicalagin, an active
pomegranate component, is a new inhibitor of PDIA3 reductase activity,” *Biochimie*, vol. 147, pp. 122–129, 2018.

[78] E. Willenbacher, S. Z. Khan, S. C. A. Mujica et al., “Curcumin: new insights into an ancient ingredient against cancer,” *International Journal of Molecular Sciences*, vol. 20, no. 8, p. 1808, 2019.

[79] B. Meng, J. Li, and H. Cao, “Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications,” *Current Pharmaceutical Design*, vol. 19, no. 11, pp. 2101–2113, 2013.

[80] H. Khan, H. Ullah, and S. M. Nabavi, “Mechanistic insights of hepatoprotective effects of curcumin: therapeutic updates and future prospects,” *Food and Chemical Toxicology*, vol. 124, pp. 182–191, 2019.

[81] X. Song, M. Zhang, E. Dai, and Y. Luo, “Molecular targets of curcumin in breast cancer (review),” *Molecular Medicine Reports*, vol. 19, no. 19, pp. 23–29, 2019.

[82] A. Shakeri, M. R. Zirak, A. Wallace Hayes, R. Reiter, and G. Karimi, “Curcumin and its analogues protect from endoplasmic reticulum stress: mechanisms and pathways,” *Pharmacological Research*, vol. 146, Article ID 104335, 2019.

[83] K. Mahkamova, N. Latar, S. Aspinall, and A. Meeson, “Hypoxia increases thyroid cancer stem cell–enriched side population,” *World Journal of Surgery*, vol. 42, no. 2, pp. 350–357, 2018.

[84] C. Tan, L. Zhang, X. Cheng et al., “Curcumin inhibits hypoxia-induced migration in K1 papillary thyroid cancer cells,” *Experimental Biology and Medicine*, vol. 240, no. 7, pp. 925–935, 2015.

[85] J. Zhang, J. Yu, R. Xie, W. Chen, and Y. Lv, “Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways,” *Natural Product Research*, vol. 30, no. 16, pp. 1858–1861, 2016.

[86] F. Stancioiu, D. Mihai, G. Z. Papadakis, A. Tsatsakis, D. A. Spandidos, and C. Badiu, “Treatment for benign thyroid nodules with a combination of natural extracts,” *Molecular Medicine Reports*, vol. 20, no. 20, pp. 2332–2338, 2019.

[87] H. Ye and I. C. Shaw, “Food flavonoid ligand structure/estrogen receptor-a affinity relationships-toxicity or food functionality?” *Food and Chemical Toxicology*, vol. 129, pp. 328–336, 2019.

[88] C. Gonçalves, M. de Freitas, and A. Ferreira, “Flavonoids, thyroid iodide uptake and thyroid cancer-a review,” *International Journal of Molecular Sciences*, vol. 18, no. 6, p. 1247, 2017.

[89] M. C. de Souza Dos Santos, C. F. L. Gonçalves, M. Vaisman, A. C. F. Ferreira, and D. P. de Carvalho, “Impact of flavonoids on thyroid function,” *Food and Chemical Toxicology*, vol. 49, no. 10, pp. 2495–2502, 2011.

[90] M. Messina and G. Redmond, “Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature,” *Thyroid*, vol. 16, no. 3, pp. 249–258, 2006.

[91] B. Šotić-Jurjević, B. Filipović, E. K. Wirth et al., “Soy isoflavones interfere with thyroid hormone homeostasis in orchidectomized middle-aged rats,” *Toxicology and Applied Pharmacology*, vol. 278, no. 2, pp. 124–134, 2014.

[92] C. Bennet-Pellisero, “Risks and benefits of phytoestrogens,” *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 19, no. 6, pp. 477–483, 2016.

[93] W. De-Eknamkul, K. Umehara, O. Monthanakantirat et al., “QSAR study of natural estrogen-like isoflavonoids and diphenolics from Thai medicinal plants,” *Journal of Molecular Graphics and Modelling*, vol. 29, no. 6, pp. 784–794, 2011.

[94] K. Morteza-Semnani and Z. Ghanbarimasir, “A review on traditional uses, phytochemistry and pharmacological activities of the genus Ballota,” *Journal of Ethnopharmacology*, vol. 233, pp. 197–217, 2019.

[95] C. Rajagopal, M. B. Lankadasari, J. M. Aranjani, and K. B. Harikumar, “Targeting oncogenic transcription factors by polyphenols: a novel approach for cancer therapy,” *Pharmacological Research*, vol. 130, pp. 273–291, 2018.

[96] C. Giuliani, Y. Noguchi, N. Harii et al., “The flavonoid quercetin regulates growth and gene expression in rat FRTL-5 thyroid cells,” *Endocrinology*, vol. 149, no. 1, pp. 84–92, 2008.

[97] C. Giuliani, I. Bucci, S. Di Santo et al., “The flavonoid quercetin inhibits thyroid-restricted genes expression and thyroid function,” *Food and Chemical Toxicology*, vol. 66, pp. 23–29, 2014.

[98] R. Shen and J. H. Wang, “The effect of icariin on immunity and its potential application,” *American Journal of Clinical and Experimental Immunology*, vol. 7, no. 7, pp. 50–56, 2018.

[99] S. Ji, X. Chang, S. Deng, and D. Fan, “Icariin enhances the chemosensitivity of cisplatin-resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway,” *International Journal of Oncology*, vol. 54, no. 6, pp. 1933–1942, 2019.

[100] H. L. Tan, K. G. Chan, P. Puspurajah et al., “Anti-cancer properties of the naturally occurring aphydiosiaic: icariin and its derivatives,” *Frontiers in Pharmacology*, vol. 7, p. 191, 2016.

[101] P. Wang, J. Zhang, X. Xiong et al., “Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells,” *Oncology Reports*, vol. 41, no. 41, pp. 2321–2328, 2019.

[102] P. Zhou, S. Gross, J.-H. Liu et al., “Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-κB and MAPK signaling pathways,” *The FASEB Journal*, vol. 24, no. 12, pp. 4722–4732, 2010.

[103] Y.-C. Hseu, Y.-C. Huang, V. Thiyagarajan et al., “Anticancer activities of chalcone flavokawain B from Alpinia pricei Hayata in human lung adenocarcinoma (A549) cells via induction of reactive oxygen species-mediated apoptotic and autophagic cell death,” *Journal of Cellular Physiology*, vol. 234, no. 10, pp. 17514–17526, 2019.

[104] S. K. Yip, N. Abu, N. Akhtar et al., “Gene expression analysis reveals the concurrent activation of proapoptotic and antioxidant-defensive mechanisms in Flavokawain B-treated cervical cancer HeLa cells,” *Integrative Cancer Therapies*, vol. 16, no. 3, pp. 373–384, 2017.

[105] C. Sarasquete, M. Úbeda-Manzanares, and J. B. Ortiz-Delgado, “Toxicity and non-harmful effects of the soya isoflavones, genistein and daidzein, in embryos of the zebrafish, Danio rerio,” *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology*, vol. 211, pp. 57–67, 2018.

[106] J. Jahanafrooz, N. Motamed, B. Rinner, A. Mokhtarzadeh, and B. Baradaran, “Silibinin to improve cancer therapeutic, and B. Baradaran, “Silibinin to improve cancer therapeutic, and” *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology*, vol. 211, pp. 57–67, 2018.

[107] B. Singh, J. P. Singh, N. Singh, and A. Kaur, “Saponins in medicinal plants,” *QSAR study of natural estrogen-like isoflavonoids and diphenolics from Thai medicinal plants,* *BioMed Research International*, vol. 20, Article ID 8174345, 11 pages, 2018.
[109] W. Pan, B. Xue, C. Yang et al., "Biopharmaceutical characters and bioavailability improving strategies of ginsenosides," *Fitoterapia*, vol. 129, pp. 272–282, 2018.

[110] P. Koczurkiewicz, J. Czyż, I. Podolak et al., "Multidirectional effects of triterpene saponins on cancer cells-mini-review of in vitro studies," *Acta Biochimica Polonica*, vol. 62, no. 3, pp. 383–393, 2015.

[111] C. Hu, A. J. Lau, R. Wang, and T. K. H. Chang, "Comparative analysis of ginsenosides in human glucocorticoid receptor binding, transactivation, and transrepression," *European Journal of Pharmacology*, vol. 815, pp. 501–511, 2017.

[112] Y. Song, F. Zhao, L. Zhang, Y. Du, T. Wang, and F. Fu, "Ginsenoside Rg1 exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vitro," *Fitoterapia*, vol. 91, pp. 173–179, 2013.

[113] L. Li, X. Wang, R. Sharvan, J. Gao, and S. Qu, "Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways," *Biomedicine & Pharmacotherapy*, vol. 95, pp. 1225–1231, 2017.

[114] Y. Ito, T. Higashiyama, M. Hirokawa et al., "Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component," *Endocrine Journal*, vol. 59, no. 9, pp. 839–844, 2012.

[115] Z. Wang, Y. Ding, X. Wang et al., "Pseudolaric acid B triggers ferroptosis in glioma cells via activation of Nox4 and inhibition of xCT," *Cancer Letters*, vol. 428, pp. 21–33, 2018.

[116] C. Liu, L. Yin, J. Chen, and J. Chen, "The apoptotic effect of shikonin on human papillary thyroid carcinoma cells through mitochondrial pathway," *Tumor Biology*, vol. 35, no. 3, pp. 1791–1798, 2014.

[117] Y. Zhang, B. Sun, Z. Huang, D.-W. Zhao, and Q. Zeng, "Shikonin inhibits migration and invasion of thyroid cancer cells by downregulating DNMT1," *Medical Science Monitor*, vol. 24, pp. 661–670, 2018.

[118] X. Zou, J. Liang, J. Sun et al., "Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway," *Journal of Pharmaceutical Sciences*, vol. 131, no. 4, pp. 233–240, 2016.

[119] Y. Xiang, J. Zhao, M. Zhao, and K. Wang, "Allicin activates autophagic cell death to alleviate the malignant development of thyroid cancer," *Experimental and Therapeutic Medicine*, vol. 15, no. 4, pp. 3537–3543, 2018.

[120] C. M. Kitahara and J. A. Sosa, "The changing incidence of thyroid cancer," *Nature Reviews Endocrinology*, vol. 12, no. 11, pp. 646–653, 2016.

[121] S. M. Ferrari, P. Fallahi, M. R. Galdiero et al., "Immune and inflammatory cells in thyroid cancer microenvironment," *International Journal of Molecular Sciences*, vol. 20, no. 18, p. 4413, 2019.